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This issue of the Biomedical Journal honours the laureates of the 2018 Nobel Prize in Phys-
iology and Medicine for their ground-breaking contributions to cancer immunotherapy and
unveils the identification of essential intermediates between microtubule-targeting agents
and apoptosis. Subsequently, we learn about the hypoglycemic properties of natural
phenolic acids, how cone-beam computed tomography assists dental implant surgery and
which factors should be taken into account for salvage liver transplantation after recurrent
hepatocellular carcinoma. Further readings discuss the negative impact of bismuth shields
on computed tomography image quality, the predictive value of warning headaches for
aneurysmal subarachnoid haemorrhage and the great long-term performance of zirconia
implant abutments.Spotlight on reviews
High hopes and high honours for cancer immunotherapy
If there is one synonym for hope in the field of cancer therapy
in these recent years, then it is immunotherapy [1]. According
to the American Society of Clinical Oncology (ASCO), the
“advance of the year” in 2018 was the use of chimeric antigen
receptor (CAR) T cell immunotherapy for leukaemia and
lymphoma, an approach consisting in genetically engineered
T cells, equipped with a receptor that both recognises a spe-
cific antigen on the tumour surface, and acts as a T-cell acti-
vator [2]. Moreover, the use of tumour-associated antigens forhagen, BRIC Biotech Rese
.
g Gung University.
ublishing services by Else
s/by-nc-nd/4.0/).therapeutic cancer vaccines has lately experienced a regain in
interest [3].
In any case, one indisputable key strategy of cancer im-
munotherapies over the last decades have been immune
checkpoint inhibitors.
Fittingly, the Nobel Prize of Physiology and Medicine 2018
was awarded to two eminent figures in the field, TasukuHonjo
and James Allison, who worked respectively on the pro-
grammed death molecule-1 (PD-1) and the cytotoxic T-
lymphocyte antigen 4 (CTLA-4). Bothmolecules are implicated
in the suppression of T cell activation [Fig. 1] and their inhi-
bition is nowadays at the core of several cancer therapies.
Therefore, Pei-Wei Huang and John Wen-Cheng Chang,
themselves possessing broad experience in the fields ofarch & Innovation Centre, Anders Lund Group, Ole Maaløes Vej 5
vier B.V. This is an open access article under the CC BY-NC-ND
Fig. 1 How immune checkpoint inhibitors keep T cells awake. Engineered antibodies against CTLA-4 and PD-1, expressed at the
surface of T cells prevent inactivation of the latter by ligands located at the surface of tumour cells and other immune cells in
order to down-regulate T cell activity, allowing the immune system to mount an efficient T cell response against the tumour.
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awardees and their findings with a short but very informative
review in this issue of the Biomedical Journal [4].
First, Huang and Chang recapitulate the history and key
discoveries of the two laureates, stressing the time, perse-
verance, and patience required to complete the long and
trying road frombench to bedside, fuelled by their enthusiasm
for, and dedication to scientific research.
Honjo, for example, came across PD-1 in apoptotic T cells
in 1992 [5] and observed its role as a negative regulator of B
cells, and its absence as the cause of autoimmune diseases in
the late 90s [6,7]. As for CTLA-4, the immunoglobulin had been
identified in 1987 by the group of Pierre Golstein [8]. In 1995,
mice lacking CTLA-4 were found to display lymphoprolifer-
ative disorders and early lethality [9,10]. The same year,
Matthew Krummel and James Allison showed that CD28 and
CTLA-4 have opposing effects on T cell responses to stimula-
tion, with CD28 being activatory, and CTLA-4 inhibitory [11].
Foreshadowing their Nobel Prize, both researchers were
awarded the first Tang Award in Biopharmaceutical Science in
2014 [12]. The Taiwanese entrepreneur Samuel Yin created the
prize in order to recognise and reward efforts in research
fields essential to the 21st century, taking into account both
technological progress and ethical considerations. Of note, the
2018 Tang Award of the same category went also to the field of
cancer therapy, more specifically to the development of
tyrosine kinase inhibitors for targeted cancer treatments, and
was recently covered by another review in the Biomedical
Journal [13].
Subsequently, the authors explain in detail the current
applications of anti-PD-1 and anti-CTLA-4 drugs, separately
or in combination, and to what extent these treatments have
improved patient survival. The most outstanding example isthe case of advancedmelanoma: last year, a phase 3 trial on a
four year outcome study reported an over 40% survival rate
for patients being treated with a combination of nivolumab
(an anti-PD-1 monoclonal antibody) and ipilimumab (an
anti-CTLA-4 monoclonal antibody). This is rather impres-
sive, given that the survival rate had reached barely 10% so
far [14,15].
The remarkable success of this trial has inspired a great
range of further clinical trials for many types of cancer,
including for the treatment of earlier stages of the disease.
Huang and Chang complement their review with extensive
and complete documentation on all important ongoing trials
for immune checkpoint inhibitors in cancer. One important
milestone for the application of anti-PD-1 medication was the
US Food and Drug Administration (FDA) approval for the
tumour-agnostic indication of pembrolizumab (another anti-
PD-1 monoclonal antibody) for any kind of solid tumour dis-
playing high levels of microsatellite instability (MSI-H) and
deficientmismatch repair (dMMR) [16], the very first case of an
anti-cancer drug to be granted this level of freedom.
Ultimately, the authors provide some perspective com-
plementing the overall optimism, touching on the side effects
of immune drugs, which are of variable severity. Another
limitation to date is the fact that only a minority of patients
benefits from this type of treatment. CAR T cell therapy, for
instance, is so far limited to a restricted portion of patients
with B cell malignancies [2]. Taking the discussion a little
further, Demaria et al. point out in another recent update on
cancer immunotherapy that tumour immunity ismassively T-
cell-centred, despite the fact that innate immune responses
are crucial premises for efficient and lasting T-cell activities.
Antigen-presenting cells, such as certain dendritic cells, are
required for triggering the activation of tumour-specific CD8 T
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Natural killer (NK) cells in turn can recognise tumour cells and
attack them directly, but also stimulate an adaptive response
through the secretion of cytokines and growth factors. Tu-
mours counter these attacks with inhibitory cell surface re-
ceptors, a fact that stresses that the fitness of the innate
immune system should be taken into account as much as the
adaptive one, and the range of target tumours massively
increased [1].Spotlight on original articles
From drug to death e deciphering the interactome of
microtubule-targeting agents in prostate cancer
The incredibly fast-paced progress of techniques and tech-
nologies has radically changed our approach to decipher
molecular pathways. For the most part, the performance,
speed and accessibility of deep sequencing account for the
gigantic zoom-out on networks, shifting the focus from the
interaction between a fewmolecules to a class of molecules in
its entirety, from proteome to epitranscriptome [17]. Knowing
the potential chain reactions on the often strongly altered
interactomes of cancer cells is of crucial importance in order
to predict the (in)efficiency of specific treatments or the
combined effect of several drugs.
By way of illustration, although themain targets of the two
anti-cancer drugs Paclitaxel and Vincristine are rather well
known, their secondary targets remain elusive, as do the de-
tails of their combined action, raising concerns pertaining to
potentially unwanted secondary effects.
At the heart of this study by Delgado-Carre~no andMendez-
Callejas stands the in silico identification and experimental
validation of the main interactome nodes of these two drugs,
with a special focus on secondary targets among the pro- and
anti-apoptotic proteins [18].
The authors start with a comprehensive description of
prostate cancer features, notably the issue that most patients
with metastatic prostate cancer sooner or later become in-
dependent of androgen, and thus develop a resistance against
androgen ablation therapy (ADT). This is where more drastic
drugs become relevant, such as microtubule-targeting agents
(MTAs). Allegedly, these naturally occurring substances
caused the death of numerous hungry or bored hearse horses
that nibbled at the leaves of the yew bushes surrounding
Parisian cemeteries [19]. Paclitaxel, sold as Taxol, initially
stems from the Pacific yew,while Vincristine, sold as Oncovin,
is found in the Madagascar periwinkle. However, given that
none of these substances can tell apart good from bad mi-
crotubules, the side effects of MTAs are rather severe, ranging
from hair loss, to bleeding, and neuropathies [20], which ex-
plains why these treatments are only prescribed once more
targeted methods like ADT fail.
Nevertheless, their impact is efficient. Delgado-Carre~no
and Mendez-Callejas briefly describe the molecular mecha-
nisms of the microtubule-stabilizing agent Paclitaxel and the
microtubule-destabilizing Vincristine. Some of the corner-
stones of the process are the inactivation by phosphorylation
of the anti-apoptotic Bcl-2 protein, the accumulation of thepro-apoptotic protein Bim, and the induction of apoptosis
through caspase activation [21].
The first step of deciphering further the Paclitaxel-
Vincritine interactome is a bioinformatic one. The authors
undertake a thorough literature based research and employ
online tools to begin by identifying the essential nodes in the
target network of each drug separately. They note that the
Paclitaxel network presents a much higher number of nodes
and edges than the Vincristine network. The former com-
prises TP53, AKT1, VEGFA, JUN and CASP3 as essential nodes,
alongside BCL2, BAX and BCL2L1. Vincristine however, is
principally centred on TP53 and CASP3, which are also part of
the Paclitaxel network.
The investigation subsequently transits to the bench,
where the effects of the drugs on cell proliferation and the
induction of major cellular damage is confirmed in the
androgen-independent prostate cancer cell line PC-3, which
also carries a P53 mutation. Unsurprisingly, the cells are more
sensitive to Paclitaxel than to Vincristine.
Further experimental quantification of protein levels based
on the predicted nodes shows concomitant increase of Bim
and decrease of Bcl-2 by both substances, but diverging effects
on Bax proteins. Their levels are decreased by Paclitaxel and
increased by Vincristine, while the effect on activated caspase
3 is the opposite.
Moreover, Delgado-Carre~no et al. demonstrate that the
direct interactions between the main players mediating the
effect of the drugs differ significantly. For example, the Bim/
Bax and Bcl-2/Bax levels increased and decreased respectively
only after Paclitaxel treatment. In the case of the cellular
response to Vincristine, new interactions are uncovered,
notably between Bim and cleaved caspase 3, and the latter
with Bcl-2. Time is also considered to be an important feature
of the treatment course.
The authors conclude that although the Paclitaxel spec-
trum of action is much broader than the one of Vincristine, it
harbours the risk of conflicting effects on pro- and anti-
apoptotic pathways, while Vincristine is more specific for
cell death induction. Their observations confirm previous re-
sults on Bim acting as a tumour suppressor, which takes over
from the no longer functional P53 in promoting Bax release,
Interestingly, Vincristine induces higher Bim levels than
Paclitaxel.
Besides the confirmation that the time-course, the protein
levels, and the exact modalities of apoptosis depend on the
drug mechanism, Delgado-Carre~no and Mendez-Callejas add
valuable experimental information regarding predicted sec-
ondary targets of two MTAs in ADT-resistant, P53 negative
prostate cancer cells.Also in this issue
Original articles
The potential synergy of natural phenolic acids and hypogly-
cemic drugs.
The use of natural products, notably plant extracts, for
adjunctive therapies is rapidly gaining popularity as well as
some rigorous scientific support. Curcumin, green tea, garlic
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kitchen shelf to the medicine cabinet, and have proven their
value against a broad range of diseases, such as cancer [22],
tuberculosis [23] or Helicobacter pylori infection [24]. Aside from
their intrinsic beneficial properties, natural compounds can
display synergistic effects with medication, either enhancing
the drug's impact or dampening detrimental side effects [25].
Phenolic acids and polyphenols are regulars among the active
compounds in charge of antioxidative, antidiabetic [26], or
neuroprotective effects [27]. On these grounds, Oboh et al.
investigate in the present study [28] the influence of gallic and
tannic acid on the therapeutic properties of the antidiabetic
drug acarbose [29] in a rather surprising model system, the
fruit fly, whose metabolic functional similarities with mam-
mals are often underestimated [30]. The authors show that
although the addition of the phenolic derivatives enhance the
antioxidant and alpha-glucosidase inhibitory features of
acarbose in vitro, they do not significantly improve the glucose
lowering potential of acarbose in vivo, but displayed hypogly-
cemic effects on their own and supplementary antioxidant
qualities when combined with acarbose.
Monitoring of Schneiderian membranes between tooth
extraction and sinus lifting implant surgery by cone-beam
computed tomography
Tooth extraction has made quite the progress since the
countless vivid depictions from the Middle Ages of screaming
patients with huge pliers stuck in their mouths, when the
procedure was performed by lay barbers [31]. The same goes
for the replacement of the lost tooth by implants, although the
practice can be traced back to the Egyptians [31]. Nowadays
tooth implantation is precision work, often requiring pre-
liminary restoration of the jaw, due to bone atrophy and other
complications. Additionally, the dentist's work is frequently
impacted by the state and potential diseases of the maxillary
sinus, neighbouring the oral cavity, which can affect the
diagnosis and treatment options [32]. Detailed presurgical
assessment of the patient's anatomy is thus a basic require-
ment. Notably the integrity of the Schneiderian membrane,
the epithelium lining the maxillary cavity, ought to be pre-
served. Here, Hsu et al. perform a retrospective study on the
correlation of the sinus membrane's thickness with the sur-
rounding hard tissue next to a missing tooth, as well as the
evolution of infected membranes after tooth extraction [33].
The authors don't detect a link between membrane thickness
and bone features, and observe resolution of infection-caused
thickening after an average of three months. Moreover, they
confirm that the use of cone-beam computed tomography
reduces the risk of damaging the Schneiderian membrane
during subsequent surgery, and advise to wait about three
months before performing sinus lifting implant surgery if an
odontogenic tooth infection was present.
Important considerations for salvage liver transplantation
following recurrent hepatocellular carcinoma
Hepatocellular carcinoma (HCC) occupies the infamous forth
rank of deaths by cancer, according to the World Health
Organisation, and its incidence is increasing worldwide [34].
Treatment options drastically decrease with advanced stages
of HCC, and prognosis is relatively poor [35]. Even the drasticmethod of liver resection (LR) has a very high postoperative
recurrence rate. So far, the best option for these patients
consists in salvage liver transplantation (LT), but this option is
hampered by the limited availability of donor organs, eco-
nomic burden, risk of the operation, and the need of life-long
immunosuppressive measures [36]. Thus, determining the
combination of factors for an optimal outcome of LT is crucial
for the improvement of therapeutic strategies.
For this reason, Chan et al. review the evolution of patients
who had been subjected to liver transplantation for recurrent
HCC after primary liver resection, and search for character-
istics correlated with patient outcome in order to improve the
decision-making process for HCC therapies [37].
They find that a maximum tumour size over 5 cm at initial
resection, the exceedance of the UCSF criteria, and a period of
more than a year between post-LR HCC recurrence and LT are
independent risk factors for HCC recurrence after trans-
plantation. Therefore, advanced HCC can affect patient
outcome even after full replacement of the organ and LT
should be carried out as soon as possible in case of HCC
recurrence after resection.
Bismuth shields can negatively impact on computed
tomography image quality
The 1979 Nobel Prize of Physiology andMedicinewent to Allan
Cormack and Godfrey Hounsfield for the development of
computer assisted tomography, a method consisting in the
computer-processed assembly of multiple X-ray images into
virtual cross-sections. Nowadays, the “CT scan” technique is
an essential tool for medical imaging, and used for countless
purposes, including the detection of infarction, coronary ar-
tery disease, or complex fractures. However, the benefits
come with a cost, such as the carcinogenic potential of the
radiation [38], or damages due to intravenous contrast [39].
Bismuth shields could reduce the radiation dose to sensitive
body parts, such as the eyes, but can interfere with signal
acquisition. In order to assess the impact of bismuth shields
on scan quality depending on the distance between the region
of interest and the shield, Liao et al. performed a rigorous
study on a phantom mimicking various tissues [40]. The au-
thors conclude that bismuth shields can increasingly change
CT number accuracy and induce artefacts the closer they are
to the scanned part. They advise to limit their use to routine
CT scans where the radiosensitive organs are not close to the
diagnostic region and to avoid them in quantification-
purposed or follow-up scans.
Warning headache foretells better survival after aneurismal
subarachnoid haemorrhage
Subarachnoid haemorrhage (SAH), the bleeding into the two
inner membranes of the meninges enveloping the brain and
the spinal cord, is predominantly caused by severe trauma to
the head. Spontaneous SAH cases in turn are due to the
rupture of an intracranial aneurysm (aSAH) in 85% of all cases.
Although the survival rates have substantially increased over
the recent years, permanent cognitive impairments are com-
mon sequela [41]. Many warning symptoms have been noted,
including “thunderclap” headache, seizures, vomiting [42],
and even toothache [43], however none of them are very
specific for aSAH. Nevertheless, a better knowledge on how
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with clinical prognosis might help subsequent patient man-
agement, argue Lin et al. [44]. Their retrospective study shows
that among several characteristics that can predict survival
chances, the WFNS scale and the warning headache were the
most predictive. Paradoxically, the headache seems actually
to be a good sign, as it is associated with better survival rates,
and should thus be taken into account for prognostic
prediction.
Zirconia implant abutments display very good long-term
performances
Implant abutments are the adapters connecting the dental
implant, screwed into the bone, to a crown, bridge, or
removable denture. They were traditionally made out of
various metals, such as titanium, stainless steel, or gold [45].
More recently, zirconium has become a popular alterna-
tive, as the transition metal is both very resistant to corrosion
and does not lead to the unattractive discoloration of the peri-
implant soft tissue. Nevertheless, reports on medium- and
long-term performance on zirconia implant abutments
remain rare [46].
Here, Chen et al. review the state of 32 zirconia abutments
and all-ceramic crowns six years after implantation [47] and
observe that they display a 100% survival rate, good biological
compatibility, and outstanding aesthetic results.Conflicts of interest
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